What is the projected market valuation for the Italy glioblastoma market in 2035?

The projected market valuation for the Italy glioblastoma market in 2035 is expected to reach $155.84 Million. Read More

What was the overall market valuation in 2024?

The overall market valuation in 2024 was $102.02 Million. Read More

What is the expected CAGR for the Italy glioblastoma market from 2025 to 2035?

The expected CAGR for the Italy glioblastoma market during the forecast period 2025 - 2035 is 3.93%. Read More

Which treatment type had the highest valuation in the market segments?

Chemotherapy had the highest valuation among treatment types, ranging from $30.0 Million to $40.0 Million. Read More

What are the key players in the Italy glioblastoma market?

Key players in the market include Bristol-Myers Squibb, Merck & Co, Roche, Novartis, Eli Lilly and Company, Amgen, AstraZeneca, Pfizer, and Sanofi. Read More

Which drug type is projected to have the highest market valuation?

Temozolomide is projected to have the highest market valuation, with estimates ranging from $40.0 Million to $60.0 Million. Read More

What distribution channel is expected to generate the most revenue?

The Specialty Pharmacy distribution channel is expected to generate the most revenue, with valuations between $32.02 Million and $50.84 Million. Read More

What is the market valuation range for hospitals as an end user?

The market valuation range for hospitals as an end user is between $60.0 Million and $90.0 Million. Read More

How does the market for glioblastoma treatments appear to be segmented?

The market for glioblastoma treatments appears to be segmented into treatment types, drug types, distribution channels, and end users. Read More

What is the valuation range for immunotherapy in the treatment segment?

The valuation range for immunotherapy in the treatment segment is between $12.02 Million and $25.84 Million. Read More

Italy Glioblastoma Market

ID: MRFR/HC/48102-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Italy Glioblastoma Market Research Report By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Drug Type (Temozolomide, Bevacizumab, Carmustine, Nivolumab, Lomustine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy) and By End User (Hospitals, Clinical Research Organizations, Homecare Settings) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Treatment Type (USD Million)
  1. 4.1.1 Surgery
  2. 4.1.2 Radiation Therapy
  3. 4.1.3 Chemotherapy
  4. 4.1.4 Targeted Therapy
  5. 4.1.5 Immunotherapy
2. 4.2 Industrial Automation & Equipment, BY Drug Type (USD Million)
  1. 4.2.1 Temozolomide
  2. 4.2.2 Bevacizumab
  3. 4.2.3 Carmustine
  4. 4.2.4 Nivolumab
  5. 4.2.5 Lomustine
3. 4.3 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacy
  2. 4.3.2 Retail Pharmacy
  3. 4.3.3 Online Pharmacy
  4. 4.3.4 Specialty Pharmacy
4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinical Research Organizations
  3. 4.4.3 Homecare Settings
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 ITALY MARKET ANALYSIS BY DRUG TYPE
4. 6.4 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 ITALY MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG TYPE, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG TYPE, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Treatment Type (USD Million, 2025-2035)

Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Immunotherapy

Industrial Automation & Equipment By Drug Type (USD Million, 2025-2035)

Temozolomide
Bevacizumab
Carmustine
Nivolumab
Lomustine

Industrial Automation & Equipment By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Specialty Pharmacy

Industrial Automation & Equipment By End User (USD Million, 2025-2035)

Hospitals
Clinical Research Organizations
Homecare Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”